

# Understanding and advancing novel therapies for haematological malignancies

A Celgene-sponsored satellite symposium at the EBMT meeting, 2010

*Chair: H. Ludwig*



## Scientific programme

- 13:30–13:35**    **Welcome and introduction**
- 13:35–14:00**    **Lenalidomide: linking cellular activity with clinical outcome in multiple myeloma**  
*F. Davies (London, UK)*
- 14:00–14:20**    **Maximizing the treatment of newly diagnosed myeloma**  
*A. Palumbo (Turin, Italy)*
- 14:20–14:45**    **Realizing the benefits of long-term treatment of myeloma**  
*M. Delforge (Leuven, Belgium)*
- 14:45–15:05**    **Azacitidine: a breakthrough treatment for MDS and AML patients**  
*H. Al-Ali (Leipzig, Germany)*
- 15:05–15:25**    **Will novel agents deliver in lymphoma? The evidence and expectations**  
*A. Sureda (Barcelona, Spain)*
- 15:25–15:30**    **Closing remarks**